Catecholamine Metabolites, Clinical Outcome and A New Insight into Risk Stratification of Patients with Neuroblastoma

被引：0
|
作者：
Verly, I. R. N. [1 ,2 ,3 ]
van Kuilenburg, A. B. P. [2 ]
Abeling, N. G. G. M. [2 ]
Goorden, S. M. I. [2 ]
Fiocco, M. [4 ,5 ]
Vaz, F. M. [2 ]
van Noesel, M. M. [3 ,6 ]
Zwaan, C. M. [7 ]
Kaspers, G. J. L. [8 ]
Merks, J. H. M. [1 ]
Caron, H. N. [1 ]
Tytgat, G. A. M. [1 ,3 ]
机构：
[1] Emma Childrens Hosp, Paediat Oncol Haematol, Acad Med Ctr, Amsterdam, Netherlands
[2] Emma Childrens Hosp, Lab Genet Metab Dis, Acad Med Ctr, Amsterdam, Netherlands
[3] Prinses Maxima Ctr Paediat Oncol, Paediat Oncol, Utrecht, Netherlands
[4] Leiden Univ, Med Stat & Bioinformat, Med Ctr, Leiden, Netherlands
[5] Leiden Univ, Math Inst, Leiden, Netherlands
[6] Univ Med Ctr Utrecht, Paediat, Utrecht, Netherlands
[7] Sophia Childrens Univ Hosp, Paediat Oncol Haematol, Erasmus Med Ctr, Rotterdam, Netherlands
[8] Vrije Univ Amsterdam, Paediat Oncol Haematol, Med Ctr, Amsterdam, Netherlands
来源：
PEDIATRIC BLOOD & CANCER | 2016年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-0544
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [1] URINARY CYSTATHIONINE, CATECHOLAMINE, AND METABOLITES IN PATIENTS WITH NEUROBLASTOMA
    HELSON, L
    SCHWARTZ, MK
    BETHUNE, V
    FLEISHER, M
    MURPHY, ML
    CLINICAL CHEMISTRY, 1972, 18 (07) : 613 - &
  • [2] URINARY CATECHOLAMINE METABOLITES AS MARKER FOR RELAPSE IN HIGH-RISK NEUROBLASTOMA
    Matser, Yvette
    Samim, Atia
    Van Der Ham, Maria
    De Sain-Van Der Velden, Monique
    Verhoeven-Duif, Nanda
    Fiocco, Marta
    Van Grotel, Martine
    Kraal, Kathelijne
    Dierselhuis, Miranda
    Van Eijkelenburg, Natasha
    Langenberg, Karin
    Van Noesel, Max
    Van Kuilenburg, Andre
    Tytgat, Godelieve
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [3] Neuroblastoma: clinical and biological approach to risk stratification and treatment
    Tolbert, Vanessa P.
    Matthay, Katherine K.
    CELL AND TISSUE RESEARCH, 2018, 372 (02) : 195 - 209
  • [4] Neuroblastoma: clinical and biological approach to risk stratification and treatment
    Vanessa P. Tolbert
    Katherine K. Matthay
    Cell and Tissue Research, 2018, 372 : 195 - 209
  • [5] Catecholamine excretion profiles identify clinical subgroups of neuroblastoma patients
    Verly, I. R. N.
    Leen, R.
    Meinsma, J. R.
    Hooijer, G. K. J.
    Savci-Heijink, C. D.
    van Nes, J.
    Broekmans, M.
    Wanders, R. J. A.
    van Kuilenburg, A. B. P.
    Tytgat, G. A. M.
    EUROPEAN JOURNAL OF CANCER, 2019, 111 : 21 - 29
  • [6] Clinical outcome and risk stratification in Brugada syndrome
    Wada, Tadashi
    Morita, Hiroshi
    JOURNAL OF ARRHYTHMIA, 2013, 29 (02) : 100 - 109
  • [7] IMAGING OF NEUROBLASTOMA IN PATIENTS IDENTIFIED BY MASS-SCREENING USING URINARY CATECHOLAMINE METABOLITES
    TANABE, M
    YOSHIDA, H
    OHNUMA, N
    IWAI, J
    TAKAHASHI, H
    JOURNAL OF PEDIATRIC SURGERY, 1993, 28 (04) : 617 - 621
  • [8] Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
    Benites, Bruno Deltreggia
    Costa Lima, Carolina Silva
    Lorand-Metze, Irene
    Delamain, Marcia Torresan
    Oliveira, Gislaine Borba
    de Almeida, Daiane
    de Souza, Carmino Antonio
    Vassallo, Jose
    Barbosa Pagnano, Katia Borgia
    CLINICS, 2013, 68 (03) : 339 - 343
  • [9] INSIGHT AND THE CLINICAL OUTCOME OF SCHIZOPHRENIC-PATIENTS
    MCEVOY, JP
    FRETER, S
    EVERETT, G
    GELLER, JL
    APPELBAUM, P
    APPERSON, LJ
    ROTH, L
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 1989, 177 (01) : 48 - 51
  • [10] New insight into clinical risk scores for patients with acute coronary syndromes
    Morrow, DA
    AMERICAN HEART JOURNAL, 2003, 146 (05) : 754 - 756
12345